Cargando…

Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study

BACKGROUND: Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb(®) unintentionally adsorbs vancomycin. This study aimed to quantify vancomycin elimination by CytoSorb(®). METHODS: Critically ill pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Scharf, Christina, Weinelt, Ferdinand, Schroeder, Ines, Paal, Michael, Weigand, Michael, Zoller, Michael, Irlbeck, Michael, Kloft, Charlotte, Briegel, Josef, Liebchen, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124739/
https://www.ncbi.nlm.nih.gov/pubmed/35599248
http://dx.doi.org/10.1186/s13613-022-01017-5
_version_ 1784711789438566400
author Scharf, Christina
Weinelt, Ferdinand
Schroeder, Ines
Paal, Michael
Weigand, Michael
Zoller, Michael
Irlbeck, Michael
Kloft, Charlotte
Briegel, Josef
Liebchen, Uwe
author_facet Scharf, Christina
Weinelt, Ferdinand
Schroeder, Ines
Paal, Michael
Weigand, Michael
Zoller, Michael
Irlbeck, Michael
Kloft, Charlotte
Briegel, Josef
Liebchen, Uwe
author_sort Scharf, Christina
collection PubMed
description BACKGROUND: Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb(®) unintentionally adsorbs vancomycin. This study aimed to quantify vancomycin elimination by CytoSorb(®). METHODS: Critically ill patients with sepsis or septic shock receiving continuous renal replacement therapy and CytoSorb(®) treatment during a prospective observational study were included in the analysis. Vancomycin pharmacokinetics was characterized using population pharmacokinetic modeling. Adsorption of vancomycin by the CytoSorb(®) was investigated as linear or saturable process. The final model was used to derive dosing recommendations based on stochastic simulations. RESULTS: 20 CytoSorb(®) treatments in 7 patients (160 serum samples/24 during CytoSorb(®)-treatment, all continuous infusion) were included in the study. A classical one-compartment model, including effluent flow rate of the continuous hemodialysis as linear covariate on clearance, best described the measured concentrations (without CytoSorb(®)). Significant adsorption with a linear decrease during CytoSorb(®) treatment was identified (p < 0.0001) and revealed a maximum increase in vancomycin clearance of 291% (initially after CytoSorb(®) installation) and a maximum adsorption capacity of 572 mg. For a representative patient of our cohort a reduction of the area under the curve (AUC) by 93 mg/L*24 h during CytoSorb(®) treatment was observed. The additional administration of 500 mg vancomycin over 2 h during CytoSorb(®) attenuated the effect and revealed a negligible reduction of the AUC by 4 mg/L*24 h. CONCLUSION: We recommend the infusion of 500 mg vancomycin over 2 h during CytoSorb(®) treatment to avoid subtherapeutic concentrations. Trial registration NCT03985605. Registered 14 June 2019, https://clinicaltrials.gov/ct2/show/NCT03985605
format Online
Article
Text
id pubmed-9124739
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-91247392022-05-24 Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study Scharf, Christina Weinelt, Ferdinand Schroeder, Ines Paal, Michael Weigand, Michael Zoller, Michael Irlbeck, Michael Kloft, Charlotte Briegel, Josef Liebchen, Uwe Ann Intensive Care Research BACKGROUND: Hemadsorption of cytokines is used in critically ill patients with sepsis or septic shock. Concerns have been raised that the cytokine adsorber CytoSorb(®) unintentionally adsorbs vancomycin. This study aimed to quantify vancomycin elimination by CytoSorb(®). METHODS: Critically ill patients with sepsis or septic shock receiving continuous renal replacement therapy and CytoSorb(®) treatment during a prospective observational study were included in the analysis. Vancomycin pharmacokinetics was characterized using population pharmacokinetic modeling. Adsorption of vancomycin by the CytoSorb(®) was investigated as linear or saturable process. The final model was used to derive dosing recommendations based on stochastic simulations. RESULTS: 20 CytoSorb(®) treatments in 7 patients (160 serum samples/24 during CytoSorb(®)-treatment, all continuous infusion) were included in the study. A classical one-compartment model, including effluent flow rate of the continuous hemodialysis as linear covariate on clearance, best described the measured concentrations (without CytoSorb(®)). Significant adsorption with a linear decrease during CytoSorb(®) treatment was identified (p < 0.0001) and revealed a maximum increase in vancomycin clearance of 291% (initially after CytoSorb(®) installation) and a maximum adsorption capacity of 572 mg. For a representative patient of our cohort a reduction of the area under the curve (AUC) by 93 mg/L*24 h during CytoSorb(®) treatment was observed. The additional administration of 500 mg vancomycin over 2 h during CytoSorb(®) attenuated the effect and revealed a negligible reduction of the AUC by 4 mg/L*24 h. CONCLUSION: We recommend the infusion of 500 mg vancomycin over 2 h during CytoSorb(®) treatment to avoid subtherapeutic concentrations. Trial registration NCT03985605. Registered 14 June 2019, https://clinicaltrials.gov/ct2/show/NCT03985605 Springer International Publishing 2022-05-23 /pmc/articles/PMC9124739/ /pubmed/35599248 http://dx.doi.org/10.1186/s13613-022-01017-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Scharf, Christina
Weinelt, Ferdinand
Schroeder, Ines
Paal, Michael
Weigand, Michael
Zoller, Michael
Irlbeck, Michael
Kloft, Charlotte
Briegel, Josef
Liebchen, Uwe
Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
title Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
title_full Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
title_fullStr Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
title_full_unstemmed Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
title_short Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
title_sort does the cytokine adsorber cytosorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124739/
https://www.ncbi.nlm.nih.gov/pubmed/35599248
http://dx.doi.org/10.1186/s13613-022-01017-5
work_keys_str_mv AT scharfchristina doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy
AT weineltferdinand doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy
AT schroederines doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy
AT paalmichael doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy
AT weigandmichael doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy
AT zollermichael doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy
AT irlbeckmichael doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy
AT kloftcharlotte doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy
AT briegeljosef doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy
AT liebchenuwe doesthecytokineadsorbercytosorbreducevancomycinexposureincriticallyillpatientswithsepsisorsepticshockaprospectiveobservationalstudy